The average biotech P/E ended the quarter at 27.4, about 1.6x big pharma's average P/E of 17.3. But biotech's average multiple drops to 22.2, only 1.28x that of big pharma, when Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is excluded. Regeneron, which was added to the